DSIJ Mindshare

New Drug Launch: Transforming Cardiometabolic Care in India

Glenmark Pharmaceuticals Ltd, a prominent global pharmaceutical company, has expanded its cardiometabolic portfolio by launching Empagliflozin and its fixed-drug combinations in India.

DSIJ Intelligence-1 0 315 Article rating: 5.0

The company continues to strengthen its presence in the cardiometabolic care segment, addressing the rising prevalence of diabetes and cardiovascular diseases in India.

Swiggy Unveils Ambitious Sustainability Initiatives at 2025 Summit

Swiggy Limited, a leading on-demand convenience platform in India, announced a series of ambitious sustainability initiatives at the Swiggy Sustainability Summit 2025.

DSIJ Intelligence-1 0 626 Article rating: 5.0

The summit emphasized Swiggy's dedication to creating sustainable, inclusive growth through technological innovation and strategic partnerships.

 

RSS
First510511512513515517518519Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR